Hedera

Hedera Dx is a Swiss oncology diagnostics company dedicated to streamlining the adoption of liquid biopsy in clinical practice. The company's flagship platform, Hedera Prime, provides an end-to-end solution for blood-based molecular profiling, enabling hospitals and laboratories to perform complex genomic analysis in-house. By focusing on circulating tumor DNA (ctDNA) analysis, Hedera Dx aims to improve patient access to personalized cancer treatments and therapy monitoring. Their approach integrates laboratory workflows with advanced bioinformatics to deliver actionable clinical insights for various solid tumors. The company specifically targets the logistical and technical barriers that currently limit the widespread adoption of liquid biopsy in standard care.